Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer

被引:17
|
作者
Mendoza, Dexter P. [1 ]
Lin, Jessica J. [2 ,3 ]
Rooney, Marguerite M. [2 ,3 ]
Chen, Tianqi [4 ]
Sequist, Lecia V. [2 ,3 ]
Shaw, Alice T. [2 ,3 ]
Digumarthy, Subba R. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
ALK; anaplastic lymphoma kinase; lung cancer; metastasis; FACTOR RECEPTOR MUTATION; EML4-ALK FUSION GENE; CLINICORADIOLOGIC CHARACTERISTICS; OPEN-LABEL; CRIZOTINIB; ADENOCARCINOMA; FISH; EGFR; GEFITINIB; ALECTINIB;
D O I
10.2214/AJR.19.21982
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. ALK rearrangements are an established targetable oncogenic driver in non-small cell lung cancer (NSCLC). The goal of this study was to determine the imaging features of the primary tumor and metastatic patterns in advanced ALK-rearranged (ALK+) NSCLC that may be different from those in EGFR-mutant (EGFR+) or EGFR/ALK wild-type (EGFR-/ALK-) NSCLC. MATERIALS AND METHODS. Patients with advanced ALK+, EGFR+, or EGFR-/ ALK- NSCLC were retrospectively identified. Two radiologists concurrently assessed the imaging features of the primary tumor and the distribution of metastases in these patients. RESULTS. We identified a cohort of 333 patients with metastatic NSCLC (119 ALK+ cases, 116 EGFR+ cases, and 98 EGFR-/ALK- cases). Compared with EGFR+ and EGFR-/ ALK- NSCLC, the primary tumor in ALK+ NSCLC was more likely to be located in the lower lobes (53% of ALK+, 34% of EGFR+, and 36% of EGFR-/ALK- tumors; p < 0.05), less likely to be subsolid (1% of ALK+, 11% of EGFR+, and 8% of EGFR-/ALK- tumors; p < 0.02), and less likely to have air bronchograms (7% of ALK+, 28% of EGFR+, and 29% of EGFR-TALK- tumors; p < 0.01). Compared with EGFR+ and EGFR-TALK- tumors, ALK+ tumors had higher frequencies of distant nodal metastasis (20% of ALK+ tumors vs 2% of EGFR+ and 9% of EGFR-/ALK- tumors; p < 0.05) and lymphangitic carcinomatosis (37% of ALK+ tumors vs 12% of EGFR+ and 12% of EGFR-/ALK- tumors; p < 0.01), but ALK+ tumors had a lower frequency of brain metastasis compared with EGFR+ tumors (24% vs 41%; p = 0.01). Although there was no statistically significant difference in the frequencies of bone metastasis among the three groups, sclerotic bone metastases were more common in the ALK+ tumors (22% vs 7% of EGFR+ tumors and 6% of EGFR-/ALK- tumors; p < 0.01). CONCLUSION. Advanced ALK+ NSCLC has primary tumor imaging features and patterns of metastasis that are different from those of EGFR+ or EGFR-ALK- wild type NSCLC at the time of initial presentation.
引用
收藏
页码:766 / 774
页数:9
相关论文
共 50 条
  • [21] Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
    Tabbo, Fabrizio
    Passiglia, Francesco
    Novello, Silvia
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (01)
  • [22] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [23] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Pan, Yue
    Deng, Chao
    Qiu, Zhenhua
    Cao, Chenghui
    Wu, Fang
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
    Awad, Mark
    Mastini, Cristina
    Patino, Rafael
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy
    Adeni, Anika
    Lydon, Christine
    Janne, Pasi
    Chiarle, Roberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1163
  • [25] Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities
    Chu, Li
    Ni, Jianjiao
    Yang, Xi
    Tong, Tong
    Wang, Jialei
    Yin, Fang
    Li, Ruimin
    Li, Yida
    Zou, Liqing
    Li, Yuan
    Xie, Congying
    Li, Guodong
    Zhu, Zhengfei
    [J]. JOURNAL OF CANCER, 2019, 10 (26): : 6660 - 6665
  • [26] Brigatinib, a new treatment option in ALK-rearranged advanced non-small cell lung carcinoma
    Leprieur, Etienne Giroux
    Wislez, Marie
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S173 - S176
  • [27] Clinical experience in patients with advanced ALK-Rearranged non-small cell lung cancer and brain metastases in China
    Han, Y.
    Ren, K.
    Zhang, H.
    Sun, L.
    Ren, X.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [28] Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
    Blasco, Rafael B.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [29] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [30] The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srinivasamaharaj, Srividya
    Salame, Bilal Khameze
    Rios-Perez, Jorge
    Kloecker, Goetz
    Perez, Cesar A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1227 - 1233